Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Agren, H.: Symptom Patterns in Unipolar and Bipolar Depression Correlating with Monoamine Metabolites in the Cerebrospinal Fluid. I. General Patterns. Psychiatry Res. 3: S. 211–223, 1980.PubMedCrossRefGoogle Scholar
  2. 2.
    Alexanderson, B.: Pharmacokinetics of Desmethylimipramine and Nortriptyline in Man after Single and Multiple Oral Doses. Eur. J. clin. Pharmacol. 5: S. 1–10, 1972.CrossRefGoogle Scholar
  3. 3.
    AMDP, Arbeitsgemeinschaft für Methodik und Dokumentation in der Psychiatrie (Hrsg.): Das AMDP-System: Manual zur Dokumentation psychiatrischer Befunde. Springer: Berlin/Heidelberg/New York 1979.Google Scholar
  4. 4.
    Arnold, O. H.: Zur Frage der Abwandlung depressiver Verläufe nach Antidepressiv Therapie. In: Das depressive Syndrom. Hippius, H., Selbach, H. (Hrsg.). Urban & Schwarzenberg: München 1969.Google Scholar
  5. 5.
    Asberg, M., Bertilsson, L., Martensson, B., Scalia-Tomba, G. P., Thoren, P., Traskman-Bendz, C.: CSF Monoamine Metabolites in Melancholia. Acta psychiatr. stand. 69: S. 201–219, 1984.CrossRefGoogle Scholar
  6. 6.
    Asberg, M., Cronholm, B., Sjöqvist, F., Tuch, D.: Relationship between Plasma Level and Therapeutic Effect of Nortriptyline. Brit. Med. J. 3: S. 331–338, 1971.PubMedCrossRefGoogle Scholar
  7. 7.
    Ashcroff, G. W., Dow, R. C., Yates, C. M., Pullar, J. A.: Significance of Lumbar CSF Metabolite Measurements in Affective Illness. I.: CNS and Behavioural Pharmacology Tuomisto, J. Paasomen, M. K. (Hrsg.). University of Helsinki press. Finnland: S. 277–284, 1976.Google Scholar
  8. 8.
    Avery, D., Llbrano, A.: Depression Treated with Imipramine and ECT: The De Carolis Study Reconsidered. Am. J. Psychiatry 136, 4B, 1979.Google Scholar
  9. 9.
    Axelrod, J., Whitely, L., Hertting, G.: Effect of Psychotropic Drugs on the Uptake of 3H-norepinephrine by Tissues. Science 133: S. 383–384, 1961.PubMedCrossRefGoogle Scholar
  10. 10.
    Baldwin, R. C.: Delusional and Non-delusional Depression in Late Life: Evidence for a Distinct Subtype. Brit. J. Psychiatry 152: S. 39–44, 1988.CrossRefGoogle Scholar
  11. 11.
    Banerjee, S. P., Kung, L. S., Riggi, S. J., Chanda, S. K.: Development of ß-Adrenergic Receptor Subsensitivity by Antidepressants. Nature 268: S. 455–456, 1977.PubMedCrossRefGoogle Scholar
  12. 12.
    Barker, W. A., Eccleston, D.: The Treatment of Chronic Depression. An Illustrative Case. Brit. J. Psychiat. 144: S. 317–319, 1984.PubMedCrossRefGoogle Scholar
  13. 13.
    Barnes, R. F., Veith, R. C., Borson, S., Verkey, J., Raskind, M. A., Halter, J. B.: High levels of Catecholamines in Dexamethason Resistant Depressed Patients. Am J. Psychiatry 140: S. 1623–1625, 1983.PubMedGoogle Scholar
  14. 14.
    Baumann, U., Angst, J.: AMP-System: Verlaufsanalysen psychologischer und somatischer Symptome. Arch. Psychiat. Nervenkr. 223: S. 227–238, 1977.PubMedCrossRefGoogle Scholar
  15. 15.
    Beckmann, H., Goodwin, F. K.: Antidepressant Responses to Tricyclics and Urinary MHPG in Unipolar Patients. Arch. Gen. Psychiatry 32: S. 17–21, 1975.PubMedCrossRefGoogle Scholar
  16. 16.
    Beckmann, H., Goodwin, F. K.: Urinary MHPG in Subgroups of Depressed Patients and Normal Controls. Neuropsychobiology 6: S. 91–100, 1980.PubMedCrossRefGoogle Scholar
  17. 17.
    Beckmann, H., Murphy, D. L.: Phenelzine in Depressed Patients. Effects on Urinary MHPG Excretion in Relation to Clinical Response. Neuro-psychobiology 3: S. 49–55, 1977.Google Scholar
  18. 18.
    Berger, P. A., Faull, K. F., Kilkowski, J., Anderson, P. J., Kramer, H., Davis, K.L., Barchas, J. D.: CSF Monoamine Metabolites in Depression and Schizophrenia. Am. J. Psychiatry 137: S. 174–180, 1980.PubMedGoogle Scholar
  19. 19.
    Bergstrom, D. A., Kellar, P., Kenneth, J. K.: Adrenergic and Serotonergic Receptor Binding in Rat Brain after Chronic Desmethylimipramine Treatment. J. Pharmaco. Exp. Ther. 209: S. 256–261, 1979.Google Scholar
  20. 20.
    Berlant, J. L.: Neuroleptics and Reserpine in Refractory Psychoses. J. Clin. Psychopharmacol. 6: S. 180–184, 1986.PubMedCrossRefGoogle Scholar
  21. 21.
    Berner, P., Kryspin-Exner, K., Pöldinger, W.: Therapy Possibilities for Therapy-Resistant Depressions. Pharmakopsychiat. 7: S. 189–193, 1974.CrossRefGoogle Scholar
  22. 22.
    Bertilsson, L., Mellström, B., Sjöqvist, F.: Pronounced Inhibition of Noradrenaline Uptake by 10-hydroxy-metabolites of Nortriptyline. Life Sci. 25: S. 1285–1292, 1979.PubMedCrossRefGoogle Scholar
  23. 23.
    Betzler-Franke, M.: Klinische Untersuchungen zum Vergleich Amitriptylin-N-Oxid mit Amitriptylin. Inaug. Dissertation. LudwigMaximilians-Universität München 1988.Google Scholar
  24. 24.
    Bickel, H. M.: Metabolism of Antidepressants. In: Psychotropic Agents, Part i, Antipsychotics and Antidepressants. Hofmeister, F., Stille, G. (Hrsg.). Springer: Heidelberg/Berlin/New York 1980.Google Scholar
  25. 25.
    Bielski, R. J., Friedl, R. O.: Prediction of Tricyclic Antidepressant Response: Acritical Review. Arch. Gen. Psychiatry 33: S. 1479–1489, 1976.PubMedCrossRefGoogle Scholar
  26. 26.
    Borbe, H. O., Müller, W. E.: Amitriptylinoxid. Ein Fortschritt in der Therapie mit Antidepressiva? Die Med. Welt 35: S. 1438–1442, 1984.Google Scholar
  27. 27.
    Borbe, H. O., Zierenberg, O.: Amitriptylinoxide: Receptorbinding Profile Compared with other Antidepressant Drugs. Pharmacopsychiat. 18: S. 413–419, 1985.CrossRefGoogle Scholar
  28. 28.
    Borromei, A.: A New Antidepressant Agent: Amitriptyline-N-oxide. In: Typical and Atypical Antidepressants: Clinical Practice. Costa, E., Racagni, G. (Hrsg.). S. 43–47. Raven Press: New York 1982.Google Scholar
  29. 29.
    Breyer-Pfaff, U., Ewert, M., Wiatr, R.: Comparative Single Dose Kinetics of Amitriptyline and its N-oxid in a Volunteer. Arzneim. Forsch./Drig. Res. 28: S. 1916, 1978.Google Scholar
  30. 30.
    Britton, D. R., El-Wardany, Z. S., Brown, C. P., Bianchine, J. R.: Clinical Pharmacokinetics of Selected Psychotropic Drugs. In: Handbook of psychopharmacology. Iverson, L. L., Iverson, S. D., Snyder, S. H. (Hrsg.). Plenum Press: New York 1978.Google Scholar
  31. 31.
    Brunello, N., Barbaccia, M. L., Chuang, D. M., Costa, E.: Down-Regulation of Beta-Adrenergic Receptors Following Repeated Injection of Desmethylimipramine: Permissive Role of Serotonergic Axons. Neuro-pharmacology 21: S. 1145–1149, 1982.Google Scholar
  32. 32.
    Brunello, N., Chuang, D. M., Costa, E.: Use of Specific Brain Lesions to Study the Site of Action of Antidepressants. Adv. Biosc. 40: S. 141–145, 1982.Google Scholar
  33. 33.
    Bunney, W. E. Jr., Davis, J. M.: Norepinephrine in Depressive Reactions: A Review. Arch. Gen. Psychiatry 13: S. 483–494, 1965.PubMedCrossRefGoogle Scholar
  34. 34.
    Carlsson, A.: Effects of Drugs on Amine Uptake Mechanism in the Brain. In: New Aspects of Storage and Release Mechanism of Catecholamines. Schürmann, H. J., Kroneberg, G. (Hrsg.). S. 223–233. Springer: Berlin/ Heidelberg/New York 1970.CrossRefGoogle Scholar
  35. 35.
    Carlsson, A.: Durrent Theories on the Mode of Action of Antidepressant Drugs. Adv. Biochem. Psychopharmacol. 39. In: Frontiers in Biochemical and Pharmacological Research in Depression. Usdin, E. et al. (Hrsg.). S. 213–221. Raven Press: New York 1984.Google Scholar
  36. 36.
    Carlsson, A., Hillari, N. A.: Release of Adrenalin from the Adrenal Medulla of Rabbits Produced by Reserpine, Kgl. Fysigr. Sällsk. Luna Förh. 26, 1956.Google Scholar
  37. 37.
    Cassano, G. B., Conti, L., Massimetti, G., Fornaro, P.: A Controlled Clinical Trial between Amitriptyline and its N-oxide Metabolite. Psychopharmacol. Bull. 19: S. 98–103, 1983.Google Scholar
  38. 38.
    Charney, D. S., Heninger, G. R.: Noradrenergic Function and the Mechanism of Action of Antianxiety Treatment. II. The Effect of Long-term Imipramine Treatment. Arch. Gen. Psychiatry 42: S. 473–481, 1985.PubMedCrossRefGoogle Scholar
  39. 39.
    Cohen, B. M., Baldessarini, R. J.: Tolerance to Therapeutic Effects of Antidepressants. Am. J. Psychiatry 142: S. 489–490, 1985.PubMedGoogle Scholar
  40. 40.
    Coppen, A.: The Biochemistry of Affective Disorders. Brit. J. Psychiatry 113: S. 1237–1264, 1967.CrossRefGoogle Scholar
  41. 41.
    Coppen, A., Ghose, K., Montgomery, S.: Continuation Therapy with Amitriptyline in Depression. Brit. J. Psychiat. 133: S. 191–198, 1978.Google Scholar
  42. 42.
    Corona, G. L., Cucchi, M. L., Santagostino, G., Frattini, P., Zerbi, F., Fenoglio, L., Savoldi, F.: Blood Noradrenaline and 5-HT Levels in Depressed Women During Amitriptyline or Lithium Treatment. Psychopharmacology 77: S. 236–241, 1982.PubMedCrossRefGoogle Scholar
  43. 43.
    Corona, G. L., Fenoglia, L., Pinelli, P., Zerbi, F.: Amitriptyline and Nortriptyline Plasma Levels and Therapeutic Response in Depressed Women. Pharmacopsych. Neuropsychopharmacol. 10: S. 299–308, 1977.Google Scholar
  44. 44.
    Crews, F. T., Paul, S. M., Goodwin, F. K.: Acceleration of ß-Receptor Desensitization in Combined Administration of Antidepressants and Phenoxybenzamine. Nature 290: S. 787–789, 1981.PubMedCrossRefGoogle Scholar
  45. 45.
    Davidson J. R., McLeod, M. N., Kurland, A. A., White, H. L.: Antidepressant Drugs Therapy in Psychotic Depression. Brit. J. Psychiatry 131: S. 493–496, 1977.CrossRefGoogle Scholar
  46. 46.
    Davidson, J. R., McLeod, M. N., Law-Yone, B., Linnoila, M.: A Comparison of Electroconvulsive Therapy and Combined Phenelzine-Amitriptyline in Refractory Depression. Arch. Gen. Psychiatry 35, 1978.Google Scholar
  47. 47.
    Davis, K. L., Hollister, L. E., Mathe, A. A., Davis, B. M., Rothpearl, A. B., Faull, K. F., Hsieh, J. Y. K., Barchas, J. D., Berger, P. A.: Neuroendocrine and Neurochemical Measurements in Depression. Am. J. Psychiatry 138: S. 1555, 1981.PubMedGoogle Scholar
  48. 48.
    DeCarolis, V., Gibert, F., Roccataglia, G.: Imipramina ed elltroshock nella terapie delle depression; analisi clinico-statistica dei risultati in 437 casi. Sistema Nervoso 1:. 29–42, 1964.Google Scholar
  49. 49.
    Denker, S. J.: Clinical Trial of Imipramine N-oxide and Amitriptyline-Noxide. Translation of Nordisk Psykiatrisk Tidsskrift 25: S. 463, 1971.CrossRefGoogle Scholar
  50. 50.
    Ebert, M. H., Post, R. M., Goodwin, F. K.: Effect of Physical Activity on Urinary MHPG Excretion in Depressed Patients. Lancet: 766, 1972.Google Scholar
  51. 51.
    Edwards, D. J.: Identification and Analysis of Alcoholic Metabolites Produced by Monoamine Oxidases from Various Phenylethylamines. In: Monoamine Oxidase: Structure, Function and Altered Functions. S. 403–412. Academic Press: New York 1979.Google Scholar
  52. 52.
    Escobar, J. I., Flemenbaum, A., Schiele, C. B.: Ch1orlmipramlne: A Double-Blind Comparison of Intravenous Versus Oral Administration in Depressed Patients. Psychopharmacologia 33: S. 111–116, 1973.PubMedCrossRefGoogle Scholar
  53. 53.
    Esler, M., Jackmann, G., Bobik, A., Kelleker, D., Jennings, G., Leonhard, P., Skews, H., Korner, P.: Determination of Norepinephrine Apparent Release Rate and Clearance in Humans. Life Sci. 25: S. 1461–1470, 1979.PubMedCrossRefGoogle Scholar
  54. 54.
    Esler, M., Jackman, G., Leonhard, P., Skews, H., Bobik, A., Korner, P.: Effect of Norepinephrine Uptake Blockers on Norepinephrine Kinetics. Clin. Pharmacol. Ther. 29: S. 12–20, 1981.PubMedCrossRefGoogle Scholar
  55. 55.
    Esler, M., Leonhard, P., Kelleker, D., Jackman, G., Bobik, A., Skews, H., Jennings, G., Korner, P.: Assessment of Neuronal Uptake of Noradrenaline in Humans: Detective Uptake in some Patients with Essential Hypertension. Clin. Exp. Pharmacol Physiol. 7: S. 535–539, 1980.PubMedCrossRefGoogle Scholar
  56. 56.
    Esler, M., Torbott, J., Schwarz, R., Leonhard, P., Bobik, A., Skews, H., Jackman, G.: The Peripheral Kinetics of Norepinephrine in Depressive Illness. Arch. Gen. Psychiatry 39: S. 295–300, 1982.PubMedCrossRefGoogle Scholar
  57. 57.
    Faucett, R. L., Litin, E. M., Achor, R. W. P.: Neuropharmacologic Action of Rauwolfia Compounds and its Psychodynamic Implications. Arch. Neuro. Psychiat. 77: S. 513–518, 1957.CrossRefGoogle Scholar
  58. 58.
    Feldman, R. D., Limbird, L. E., Nadeau, J., Fitzgerald, G. A., Robertson, D., Wood, A. J. J.: Dynamic Regulation of Leukocyte Beta Adrenergic Receptor-Agonist Interactions by Physiological Changes in Circulating Catecholamines. J. Clin. Invest. 72: S. 164–170, 1983.PubMedCrossRefGoogle Scholar
  59. 59.
    Fein, S., Paz, V., Rao, N., Lagrassa, J.: The Combination of Lithium Carbonate and a MOAI in Refractory Depressions. Am. J. Psychiatry 145: S. 249–250, 1988.PubMedGoogle Scholar
  60. 60.
    Fjalland, B.: Naunyn Schmiedebergs Arch. Exp. Path. Pharmak. 301: S. 5, 1977.CrossRefGoogle Scholar
  61. 61.
    Friehe, H., Fontaine, R.: Toxikologie von Amitriptylinoxid. Arzneim. Forsch./Drug Res. 28: S. 1898–1907, 1978.Google Scholar
  62. 62.
    Garbutt, J. C., Mayo, J. P., Gilette, G. M., Little, K. Y., Mason, G. A.: Lithium Potentiation of Tricyclic Antidepressants Following Lack of T-3 Potentiation. Am. J. Psychiatry 143: S. 1038–1039, 1986.PubMedGoogle Scholar
  63. 63.
    Garfinkel, P. E., Warsh, J. J., Stancer, A. C.: Depression: New Evidence in Support of Biological Differentiation. Am. J. Psychiatry 136: S. 535–539, 1979.PubMedGoogle Scholar
  64. 64.
    Georgotas, A., Friedman, E., Mccarthy, M., Mann, J., Krakowski, M., Siegel, R., Ferris, S.: Resistant Geriatric Depressions and Therapeutic Response to Monoamine Oxidase Inhibitors. Biol. Psychiatry 18: S. 195–205, 1983.PubMedGoogle Scholar
  65. 65.
    Gitlin, M. J., Weiner, H., Fairbanks, L., Hershman, J. M., Friedfeld, N.: Failure of T-3 to Potentiate Tricyclic Antidepressant Response. J. Affect. Disorders 13: S. 267–272, 1987.PubMedCrossRefGoogle Scholar
  66. 66.
    Glassmann, A. H., Kantor, S. J., Shostak, M.: Depression, Delusions and Drug Response. Am. J. Psychiatry 132: S. 716–719, 1975.Google Scholar
  67. 67.
    Glowinski, J., Axelrod, J., Iversen, L. L.: Regional Studies of Catecholamines in the Rat Brain. IV. Effects if Drugs on the Disposition and Metabolism of h3-norepinephrine and h3-dopamine J Pharmacol. Exp. Ther. 153: S. 30–41, 1966.PubMedGoogle Scholar
  68. 68.
    Godt, H. H., Fredslund-Alexander, K., Edhardt, A. M.: Amitriptyline-NOxid, a new Antidepressant, Comparative Clinical Assessment in Relation to Amitriptyline. Nord. Psykiatr. Tidsschrift 25: S. 237, 1971.CrossRefGoogle Scholar
  69. 69.
    Hale, A. S., Procter, A. W., Bridges, P. K.: Clomipramine, Tryptophane and Lithium in Combination in Therapy Resistant Endogenous Depression: Seven Case Studies. Brit. J. Psychiatry 151: S. 213–217, 1987.CrossRefGoogle Scholar
  70. 70.
    Hamilton, M.: A Rating Scale for Depression. J. Neurol. Neurosurg. Psychiat. 23: S. 56–62, 1960.PubMedCrossRefGoogle Scholar
  71. 71.
    Hamilton, M.: Drug Resistant Depressions. Response to E.C.T. Pharmakopsychiat. 7: S. 205–206, 1974.CrossRefGoogle Scholar
  72. 72.
    Harrer, G., Beinroth, A-S.: Multizentrische Therapiestudie mit Amitriptylinoxid — Equilibrin 60 — ein Breitband Antidepressivum. Die Med. Welt 34: S. 1473–1477, 1983.Google Scholar
  73. 73.
    Hebenstreit, G. F.: Amitriptylinoxid — eine Alternative zu den klassischen trizyklischen Antidepressiva in der Therapie depressiver Patienten. Ergebnisse einer Doppelblindstudie mit Amitriptylinoxid versus Amitriptylin. Der Praktische Arzt 522: S. 1241–1258, 1985.Google Scholar
  74. 74.
    Helmchen, H., Hippius, H.: Pharmakogene Depression. In: Das depressive Syndrom. Hippius, H., Selbach, H. (Hrsg.). Urban & Schwarzenberg: München 1967.Google Scholar
  75. 75.
    Helmchen, H., Pietzker, A.: Die psychische und soziale Dimension der neuroleptischen Langzeitmedikation. In: Therapie mit Neuroleptica. Hippius, H., Klein, H. E. (Hrsg.). Perimed: Erlangen 1983.Google Scholar
  76. 76.
    Hertting, G., Axelrod, J., Whiteby, L. G.: Effect of Drugs on the Uptake and Metabolism of H3-norepinephrine. J. Pharmacol. Exp. Ther. 134: S. 146–152, 1961.Google Scholar
  77. 77.
    Hippius, H., Jungxunz, G.: Some General Remarks to the Problem of Therapy Resistant Depression. In: Psychiatry. The State of the Art, Vol. 3. Pichot, P., Berner, P., Wolf, R., Than, R. (Hrsg.). Plenum Publishing Corporation: S. 97–104, 1985.Google Scholar
  78. 78.
    Hyttel, J.: Citalopram — Pharmacological Profile of a Specific Serotonin Uptake Inhibitor with Antidepressant Activity. Prog. Neuropsychopharmacol. Biol. Psychiatry 6: S. 277–295, 1982.PubMedCrossRefGoogle Scholar
  79. 79.
    Hyttel, J., Christensen, A. V., Fjalland, B.: Neuropharmacological Properties of Amitriptyline and their Metabolites. Acta pharmacol. toxicol. 47: S. 53–57, 1980.CrossRefGoogle Scholar
  80. 80.
    Janowsky, A. J., Steranka, L. R., Gillespie, D. D., Sulser, F.: Role of Neuronal Signal Input in the Down-regulation of Central Noradrenergic Receptor Function by Antidepressant Drugs. J. Neurochem. 39: S. 290–292, 1982.PubMedCrossRefGoogle Scholar
  81. 81.
    Janowsky, A. J., Okada, F., Manier, D., Applegate, C. D., Sulser, F.: Role of Serotonergic Input in the Regulation of the Beta-Adrenergic Receptor-coupled Adenylate Cyclase System. Science 218: S. 900–901, 1982.PubMedCrossRefGoogle Scholar
  82. 82.
    Jensen, K.: Depression in Patients Treated with Reserpine for Arterial Hypertension. Acta Psychiat. Neurol. Scand. 34: S. 195–204, 1959.Google Scholar
  83. 83.
    Johnson, R. W., Reisine, T., Spotnitz, S., Wiech, N., Ursillo, R., Yamamura, H. J.: Effect of Desipramine and Yohimbine on Alpha-2- and Beta-Adrenoceptor Sensitivity. Eur. J. Pharmac. 67.Google Scholar
  84. 84.
    Jungkunz, G.: Sind Bestimmungen von Serum-Spiegeln sinnvoll zur Therapie-Kontrolle? Diagnostik 19: S. 27–29, 1986.Google Scholar
  85. 85.
    Jungkunz, G., Holsboer, F.: Ergebnisse einer kontrollierten Untersuchung: Amitriptylin — Amitriptylin-N-Oxid. In: Depression — erkennen und behandeln. Rudolf, G. A. E., Heinrich, K. (Hrsg.). S. 118–126. Vieweg: Braunschweig 1984.Google Scholar
  86. 86.
    Jungkunz, G., Kuss, H-J.: On the Relationship of Nortriptyline: Ami-triptyline Ratio to Clinical Improvement of Amitriptyline Treated Patients. Pharmacopsychiat. 13: S. 111–116, 1980.CrossRefGoogle Scholar
  87. 87.
    Jungkunz, G., Kuss, H-J., Dieterle, D., Laakmann, G., Schmaus, M., Wittmann, M.: Vergleich der Infusionsbehandlung mit peroraler Applikation von Clomipramin bei endogenen depressiven Patienten. Eine Doppelblindstudie mit Plasmaspiegelbestimmungen. In: Tropfinfusionen in der Depressionsbehandlung. Kielholz, P., Adams, C. (Hrsg.). S. 38–48. Georg Thieme: Stuttgart/New York 1984.Google Scholar
  88. 88.
    Keller, H. H., Burkhard, W. P., da Prado, M.: Dopamine Receptor Blockade in Rat Brain after Acute and Subchronic Treatment with Tricyclic Antidepressants. In: Advances in Biochemical Psychopharmacology. Vol. 24. Costa, E., Greengard, P. (Hrsg.). Raven Press: New York 1979.Google Scholar
  89. 89.
    Kielholz, P., Terzani, S., Gastpar, M.: Behandlung der therapieresistenten Depressionen. Deutsche Med. Wochenschrift 100: S. 241–243, 1978.CrossRefGoogle Scholar
  90. 90.
    Klaiber, E. L., Broverman, D. M., Vogel, W., Kobayashi, Y.: Estrogen Therapy for Severe Persistent Depressions in Women. Arch. Gen. Psychiatry 36: S. 550–554, 1979.PubMedCrossRefGoogle Scholar
  91. 91.
    Koslow, S. H., Maas, J. W., Bowden, C. L., Davis, J. M., Hanin, J., Javaiu, J.: CSF and Urinary Biogenic Amines and Metabolites in Depression and Mania. A Controlled Univariate Analysis. Arch. Gen. Psychiatry 40: S. 999–1010.Google Scholar
  92. 92.
    Kraepelin, E.: Manic-Depressive Insanity and Paranoia. E. und S. Livingstone: Edinburg 1921.Google Scholar
  93. 93.
    Kugler, J., Johannes, K.-J., Laub, M., Tuluweit, K.: Electroencephalografic Assessment of Vigilance after Administration of Amitriptylin-N-Oxid. Arzneim. Forsch./Drug Res. 28: S. 1924–1925, 1978.Google Scholar
  94. 94.
    Kuhn, R.: Über die Behandlung depressiver Zustände mit einem Iminodibenzyl-Derivat (G 22 355). Schweiz. Med. Wschr. 87: 1329, 1957.Google Scholar
  95. 95.
    Kuss, H.-J., Jungkunz, G., Dieterle, D.: Veränderung der klinischen Wirkung des Amitriptylins durch Kombinationsbehandlung. Arzneim. Forsch./Drug Res. 30: S. 1200, 1980.Google Scholar
  96. 96.
    Kuss, H.-J., Jungkunz, G., Holsboer, F.: Amitriptyline: Looking through the therapeutic window. Lancet, feb.: S. 464–465, 1984.Google Scholar
  97. 97.
    Kuss, H.-J., Jungkunz, G., Johannes, K.-J.: Single Oral Dose Pharmacokinetics of Amitriptylinoxide and Amitriptyline in Humans. Pharmacopsychiat. 18: S. 259–262, 1985.CrossRefGoogle Scholar
  98. 98.
    Lake, C. R., Pickar, D., Ziegler, M. G., Lipper, S., Slater, S., Murphy, D. L.: High Plasma Norepinephrine Levels in Patients with Major Affective Disorder. Am. J. Psychiatry 139: S. 1315–1318, 1982.PubMedGoogle Scholar
  99. 99.
    Langer, G., Heimann, H.: Psychopharmaka, Grundlagen und Therapie. Springer: Wien/New York 1983.CrossRefGoogle Scholar
  100. 100.
    Lapin, J. P., Oxenkrug, G. F.: Intensification of the Central Serotonergic Processes as a Possible Determinant of the Thymoleptic Effect. Lancet 1: S. 132, 1969.PubMedCrossRefGoogle Scholar
  101. 101.
    Lemieux, G., Davignon, A., Genest, J.: Depressive States During Rauwolfia Therapy for Arterial Hypertension. Canad. Med. Assoc. J. 74: S. 522–526, 1956.PubMedGoogle Scholar
  102. 102.
    Leuschner, F., Neumann, W., Doppelfeld, I. S., Erdös, A., Fontaine, R., Gabbar, H. A., Graf, E.: General Pharmacology of Amitriptylinoxide. Arzneim. Forsch./Drug Res. 28: S. 1883–1893, 1978.Google Scholar
  103. 103.
    Linden, M., Müller-Oalinghausen, B., Schussler, G., Wilkeburger, H.: Dosage and Serum Levels of Amitriptyline in Depressed Outpatients under Routine Treatment Conditions: Supporting by Low Dose Therapy. Psychopharmacol. Bull. 19: S. 106–108, 1983.Google Scholar
  104. 104.
    Linnoila, M., Karoum, F., Caul, H. M., Kopin, J. J., Potter, W. Z.: Alteration of Norepinephrine Metabolism with Desimipramine and Zimelidine in Depressed Patients. Arch. Gen. Psychiatry 39: S. 1025–1028, 1982.PubMedCrossRefGoogle Scholar
  105. 105.
    Loomer, H. P., Saunders, J. C., Kline, N. S.: A Clinical and Pharmacodynamic Evaluation of Iproniazid as a Psychic Energizer. Psychiat. Res. Pub. Amer. Psychiat. Ass. 8: S. 129, 1957.Google Scholar
  106. 106.
    Louis, W. J., Doyle, A. E., Anavekar, S. N.: Plasma Noradrenaline Concentration and Blood Pressure in Essential Hypertension, Phaeochromocytoma and Depression. Clin. Sci. Mol. Med. 48: S. 2395–2425, 1975.Google Scholar
  107. 107.
    Maas, J. W., Fawcett, J., Dekirmenjion, H.: Methoxy4-hydroxyphenylglycol (MHPG) Excretion in Depressive States: A Pilot Study. Arch. Gen. Psychiatry 19: S. 129–134, 1968.PubMedCrossRefGoogle Scholar
  108. 108.
    Maas, J. W., Koslow, S. H., Davis, J. D., Katz, M., Frazer, A., Bowden, C. L., Berman, N., Gibbons, R., Stokes, P., Landis, H.: Catecholamine Metabolism and Disposition in Healthy and Depressed Subjects. Arch. Gen. Psychiatry 44: S. 337–344, 1987.PubMedCrossRefGoogle Scholar
  109. 109.
    Maitre, L., Moser, L., Baumann, P. A., Waldmeier, P C.: Amin Uptake Inhibitors: Criteria of Selectivity. Acta Psychiat. Scand. 61, Suppl. 1: S. 97–110, 1980.Google Scholar
  110. 110.
    Maj, J., Vetulani, J., Michaluk, J., Rogoz, Z., Skuza, G.: Central Action of Amitriptyline-N-oxide. Pharmacopsychiat. 15: S. 187–191, 1982.CrossRefGoogle Scholar
  111. 111.
    Major, L. F., Lake, R. C., Lipper, S.: The Central Noradrenergic System and Affective Response to MAO-Inhibitors. Prog. Neuropsychopharmacol. 3: S. 535–542, 1979.PubMedCrossRefGoogle Scholar
  112. 112.
    Mann, J. J.: Loss of Antidepressant Effect with Long-term Monoamine Oxidase Inhibitor Treatment without Loss of Monoamine Oxidase Inhibition. J. Clin. Psychopharmacol. 3: S. 363–366, 1983.PubMedCrossRefGoogle Scholar
  113. 113.
    Matussek, N.: Neurobiologie und Depression. Med. Wschr. 20: S. 109, 1966.Google Scholar
  114. 114.
    Melzacka, M., Danek, L.: Pharmacokinetics of Amitriptyline-N-oxids in Rats after Single and Prolonged Oral Administration. Pharmacopsychiatria 16: S. 30, 1983.PubMedCrossRefGoogle Scholar
  115. 115.
    Mendlewicz, J., Pinder, R. M., Stulemeijer, S. M., van Dorth, R.: Monoamine Metabolites in Cerebrospinal Fluid of Depressed Patients during Treatment with Mianserin or Amitriptyline. J. Affective Disorders 4: S. 219–226, 1982.CrossRefGoogle Scholar
  116. 116.
    Midgley, I., Hawkins, D. R., Charraud, L. F.: The Metabolic Fate of the Antidepressant Amitriptylineoxide in Man. Arzneim. Forsch./Drug Res. 28: S. 1911, 1978.Google Scholar
  117. 117.
    Moldawsky, R. J.: Tolerance to Antidepressants. Am J. Psychiatry 142: S. 1519, 1985.Google Scholar
  118. 118.
    Montigny, de, C., Grunberg, F., Mayer, A., Deschenes, J.-P.: Lithium Induces Rapid Relief of Depression in Tricyclic Antidepressant Drug Non-Responders. Brit. J. Psychiatry 138: S. 252–256, 1981.CrossRefGoogle Scholar
  119. 119.
    Müller, P.: Was sollen wir Schizophrenen raten: Medikamentöse Langzeitprophylaxe oder Intervallbehandlung? Nervenarzt 54: S. 477–485, 1983.PubMedGoogle Scholar
  120. 120.
    Müller, P., Kind, J.: Pharmacogenic Depressive Syndromes in the Course of Schizophrenic Psychoses. Arzneim. Forsch. 28: S. 1501–1502, 1978.Google Scholar
  121. 121.
    Nadjafi, A.: Die ambulante Therapie der Depression mit Equilibrin. Die Med. Welt 32: S. 1497–1500, 1981.Google Scholar
  122. 122.
    Naylor, G. J., Smith, A. H. W., Conelly, P.: A Controlled Trial of Methylene Blue in Severe Depressive Illness. Biol. Psychiatry 22: S. 65 7–659, 1987.Google Scholar
  123. 123.
    Okada, F., Manier, D. H., Janowsky, A. J., Steranka, L. R., Sulser, F.: Role of Aminergic Neuronal Input in the Down-regulation by Desipramine (DMJ) of the Norepinephrine (NE) Receptor Coupled Adenylate Cyclase System in Rat Cortex. Soc. Neurosci 8: S. 659, 1982.Google Scholar
  124. 124.
    Oppenheim, G.: A Case of Rapid Mood Cycling With Estrogen: Implications for Therpay. J. Clin. Psychiatry 45: S. 34–35, 1984.PubMedGoogle Scholar
  125. 125.
    Oreland, L., Wiberg, A., Asberg, Traskman, L., Sjostrand, L., Thoren, P., Bertilsson, L., Tybring, G.: Platelet MAO Activity and Monoamine Metabolites in Cerebrospinal Fluid in Depressed and Suicidal Patients and in Healthy Controls. Psychiatry Res. 4: S. 21–29, 1981.PubMedCrossRefGoogle Scholar
  126. 126.
    Paykel, E. S., Fleminger, R., Watson, J. P.: Psychiatric Side Effects of Anti-hypertensive Drugs other Than Reserpine. J. Clin. Psychopharmacol. 2: S. 14–39, 1982.PubMedCrossRefGoogle Scholar
  127. 127.
    Pflug, B., Engelmann, W., Gartner, H. J.: Circadin Course of Body Temperature and the Excretion of MHPG and VMA in a Patient with Bipolar Depression. J. Neural Transmission 53: S. 213–215, 1982.CrossRefGoogle Scholar
  128. 128.
    Platz, W., Bartsch, H.: Ergebnisse einer Doppelblindstudie bei stationär behandelten Patienten mit depressivem Syndrom. In: Depressionen —erkennen und behandeln. II. Rudolf, G. A. E., Heinrich, K. (Hrsg.). S. 102–117. Vieweg: Braunschweig 1984.Google Scholar
  129. 129.
    Post, R. M., Ballenger, J. C., Goodwin, F. K.: Cerebrospinal Fluid Studies of Neurotransmitter Function in Manic and Depressive Illness. In: Neurobiology of Cerebrospinal Fluid. Wood, J. H. (Hrsg.). S. 685–717. Plenum Press: New York 1980.CrossRefGoogle Scholar
  130. 130.
    Potter, W. Z., Calil, H. M., Externi, J.: Crossover Study of Zimelidine and Desipramine in Depression: Evidence for Amine Specifity. Psychopharmacol. Bull. 17: S. 26–29, 1981.PubMedGoogle Scholar
  131. 131.
    Praag, H. M. van: Monoamine and Depression. Pharmakopsychiat. 2: S. 151–160, 1969.CrossRefGoogle Scholar
  132. 132.
    Rapp, W.: Comparative Trial of Amitriptyline-N-oxide and Amitriptyline in the Treatment of Outpatients with Depressive Syndromes. Acta psychiat. scand. 58: S. 245–255, 1978.PubMedCrossRefGoogle Scholar
  133. 133.
    Rifkin, A., Quitkin, F., Rabiner, C. J., Klein, D. F.: Fluphenazine Decanoate, Fluphenazine hydrochloride Given Orally, and Placebo in Remitted Schizophrenics. Arch. Gen. Psychiatry 34: S. 43–47, 1977.PubMedCrossRefGoogle Scholar
  134. 134.
    Robins, E., Guze, S. B.: Classification of Affective Disorders — The Primary — Secondary, the Endogenous — Reactive and Neurotic — Psychotic Concept. In: Recent Advances in Psychobiology of Depressive Illness. Williams, T. A., Katz, M. M., Shields, J. A. (Hrsg.). Government Printing Office: London 1972.Google Scholar
  135. 135.
    Robinson, D. S., Cooper, T. B., Howard, D., Corcella, J., Albright, D.: Amitriptyline and Hydroxylated Metabolite Plasma Levels in Depressed Outpatients. J. Clin. Pharmacol. 5: S. 83–88, 1985.Google Scholar
  136. 136.
    Robinson, D. S., Johnson, G. A., Nies, A., Corcella, J., Cooper, Th. B., Albright, D., Howard, D.: Plasma Levels of Catecholamines and Dihydroxyphenylglycol during Antidepressant Drug Treatment. J. Clin. Psychopharmacol. 3: S. 282–287, 1983.PubMedGoogle Scholar
  137. 137.
    Roy, A., Pickar, D., Linnoila, M., Doran, A. R., Ninan, P., Paul, S. M.: Cerebrospinal Fluid Monoamine and Monoamine Metabolite Concentrations in Melancholia. Psychiatry Res. 15: S. 281–292, 1985.PubMedCrossRefGoogle Scholar
  138. 138.
    Roy, A., Pickar, D., Linnoila, M., Potter, W. Z.: Plasma Norepinephrine Level in Affective Disorders. Relationship to Melancholia. Arch. Gen. Psychiatry 42: S. 1181–1185, 1985.PubMedCrossRefGoogle Scholar
  139. 139.
    Rudorfer, M. V., Ross, R. J., Linnoila, M., Sherer, M. A., Potter, W. Z.: Exaggerated Orthostatic Responsivity of Plasma Norepinephrine in Depression. Arch. Gen. Psychiatry 42: S. 1186–1192, 1985.PubMedCrossRefGoogle Scholar
  140. 140.
    Sassim, N., Kuss, H.-J.: The Reduction of Amitriptylin-N-Oxide to Amitriptyline in Human Blood. Arzneim. Forsch./Drug Res. 32: S. 907, 1982.Google Scholar
  141. 141.
    Schatzberg, A. F., Orsulak, P. J., Rosenbaum, A. H., Maruta, T., Kruger, E. R., Cole, J. O., Schildkraut, J. J.: Toward a Biochemical Classification of Depressive Disorders: V: Heterogeneity of Unipolar Depressions. Am. J. Psychiatry 139: S. 471–475, 1982.PubMedGoogle Scholar
  142. 142.
    Schildkraut, J. J.: The Catecholamine Hypothesis of Affective Disorders: Review of Supporting Evidence. Am. J. Psychiatry 122: S. 509–522, 1965.PubMedGoogle Scholar
  143. 143.
    Schildkraut, J. J., Orsulak, P. J., Schatzberg, A. F., Gudeman, J. E., Cole, J. O., Rohde, W. A., Labrie, R. A.: Toward a Biochemical Classification of Depressive Disorders. In: Differences in Urinary Excretion of MHPG and Other Catecholamine Metabolites in Clinically Defined Subtypes of Depressions. Arch. Gen. Psychiatry 35: S. 1427–1433, 1978.PubMedCrossRefGoogle Scholar
  144. 144.
    Schmauss, M., Jungkunz, G.: Depressive Syndrome unter besonderer Berücksichtigung der larvierten Depression. Internist 27: 201–205, 1986.PubMedGoogle Scholar
  145. 145.
    Schmauss, M., Meyr, P.: Kombinationstherapie tri-und tetrazyklischer Antidepressiva mit MAO-Hemmern. Psycho 9: S. 373–374, 1983.Google Scholar
  146. 146.
    Schroder, H. G.: Klinische Erprobung von Equilibrin bei stationären depressiven Patienten. Die Med. Welt 33: S. 1071–1072, 1982.Google Scholar
  147. 147.
    Scott, J. A., Crews, F. T.: Rapid Decrease in Rat Brain Beta Adrenergic Receptor Binding During Combined Alpha-2-Antagonist Treatment. J. Pharmac. exp. Ther. 224: S. 640–646, 1983.Google Scholar
  148. 148.
    Seefried, S.: Equilibrin bei älteren depressiven Patienten. Ergebnisse einer Therapiestudie. Zeitschr. f. Allgemeinmed 35: S. 1945–1948, 1982.Google Scholar
  149. 149.
    Segal, D. S., Kuczenski, R., Mandell, A. J.: Theoretical Implications of Drug-Induced Adaptive Regulation for a Biogenic Amine Hypothesis of Affective Disorder. Biological Psychiatry 9: S. 147–159, 1974.PubMedGoogle Scholar
  150. 150.
    Seifert, G. J.: Untersuchung therapeutischen Vorgehens bei endogenen Depressionen. Eine retrospektive Studie. Inaug. Diss. LudwigMaximilians-Universität, München 1985.Google Scholar
  151. 151.
    Sethna, E. R.: A Study of Refractory Cases of Depressive Illnesses and their Response to Combined Antidepressant Treatment. Brit. J. Psychiatry 124: S. 265–272, 1974.CrossRefGoogle Scholar
  152. 152.
    Shore, A., Silver, S. L., Brodie, B. B.: Interaction of Reserpine, Serotonin and Lysergic Acid Diethylamide in Brain. Science 122: S. 284–285, 1955.PubMedCrossRefGoogle Scholar
  153. 153.
    Sieck, A., Wenzl, H., Graf, E.: Der Einfluß von Amitriptylinoxid auf experimentell induzierte Ulzera und Magensektion der Ratte. Arzneim. Forsch./Drug Res. 28: S. 1893–1894, 1978.Google Scholar
  154. 154.
    Siever, L. J., Pickar, D., Lake, C. R., Cohen, R. M., Uhde, T. W., Murphy, D. L.: Extreme Elevations in Plasma Norepinephrine Associated with Decreased a-Adrenergic Responsivity in Major Depressive Disorder: Two Case Reports. J. Clin. Psychopharmacol. 3: S. 39–41, 1983.PubMedCrossRefGoogle Scholar
  155. 155.
    Sigg, E. B., Gyermek, L., Hill, R. T.: Antagonism to Reserpine Induced Depression by Imipramine, Related Psychoactive Drugs and Some Autonomic Agents. Psychopharmacologia 7: S. 144–149, 1965.PubMedCrossRefGoogle Scholar
  156. 156.
    Sigg, E. B., Soffer, L., Gyermek, L.: Influence of Imipramine and Related Psychoactive Agents on the Effect of 5-HT and Catecholamines on the Cat Nictating Membrane. J. Pharmacol. Exp. Ther. 142: S. 13–20, 1963.PubMedGoogle Scholar
  157. 157.
    Stein, D., Avni, J.: Thyroid Hormones in the Treatment of Affective Disorders. Acta Psychiatr. Scand. 77: S. 623–636, 1988.Google Scholar
  158. 158.
    Stone, E. A.: Problems with Current Catecholamine Hypothesis of Antidepressant Agents: Speculations Leading a New Hypothesis. Behavioral and Brain Sciences 6: S. 535–577, 1983.CrossRefGoogle Scholar
  159. 159.
    Sulser, F.: Regulation and Function of Noradrenaline Receptor Systems in Brain. Psychopharmacological Aspects. Neuropharmacology 23: S. 255–261, 1984.PubMedCrossRefGoogle Scholar
  160. 160.
    Sulser, F., Janowsky, A., Okada, F., Manier, D. H., Mobley, P. L.: Regulation of Recognition and Action Function of the Norepinephrine Receptor Coupled Adenylate Cyclase Systems in Brain: Implications for the Therapy of Depression. Neuropharmacology 22: S. 425–431, 1983.PubMedCrossRefGoogle Scholar
  161. 161.
    Sulser, F., Vetulani, J., Mobley, Ph. L.: Mode of Action of Antidepressant Drugs. Biochem. Pharmacol. 27: S. 257–261, 1978.PubMedCrossRefGoogle Scholar
  162. 162.
    Tariot, P. N., Murphy, D. L., Sunderland, T., Müller, E. A., Cohen, R. M.: Rapid Antidepressant Effect of Addition of Lithium to Tranylcypromine J Clin. Psychopharmacol. 6: S. 165–167, 1986.PubMedCrossRefGoogle Scholar
  163. 163.
    Traskman, L., Asberg, M., Bertilsson, L., Cronholm, B., Mellström, B., Neckers, L. M., Sjöquist, F., Thoren, P., Tybring, G.: Plasma Levels of Chlorimipramine and its Demethyl Metabolite During Treatment of Depression. Clin. Pharm. Ther. 26: S. 600–610, 1979.Google Scholar
  164. 164.
    Träskman, L., Asberg, M., Bertilsson, L., Sjostrand, L.: Monoamine Metabolites in CSF and Suicidal Behavior. Arch. Gen. Psychiatry 38: S. 631–636, 1981.PubMedCrossRefGoogle Scholar
  165. 165.
    Veith, R. C., Raskind, M. A., Caldwell, J. H., Barnes, R. F., Gumbrecht, G., Ritchie, J. L.: Cardiovascular Effects of Tricyclic Antidepressants in Depressed Patients with Chronic Heart Disease. The New England J. Med. 306: S. 954, 1982.Google Scholar
  166. 166.
    Vernier, V. G., Hansen, H., Stone, C.: The Pharmakodynamics of Amitriptyline. In: Psychosomatic Medicine: S. 683, 1962.Google Scholar
  167. 167.
    Vetulani, J., Stawarz, R. J., Sulser, F.: Adaptive Mechanisms of the Noradrenergic Cyclic AMP Generating Systems in the Limbic Forebrain of the Rat: Adaptation to Persistent Changes in the Avialiability of Norepinephrine (NE). J. Neurochemistry 27: S. 661–666, 1978.CrossRefGoogle Scholar
  168. 168.
    Vetulani, J., Sulser, F.: Action of Various Antidepressant Treatments Reduces Reactivity of Noradrenergic Cyclic AMP-Generating System in Limbic Forebrain. Nature 257: S. 495–496, 1975.PubMedCrossRefGoogle Scholar
  169. 169.
    Wehr, T. A., Muscetolla, G., Goodwin, F. K.: Urinary 3-Methoxy4-Hydroxyphenylglycol Circadian Rhythm. Early Timing Arch. Gen. Psychiatry 35: S. 1378–1383, 1978.CrossRefGoogle Scholar
  170. 170.
    Wilk, S., Shopsin, B., Gershon, S., Suhl, M.: Cerebrospinal Fluid Levels of MHPG in Affective Disorders. Nature 235: S. 440–441, 1972.PubMedCrossRefGoogle Scholar
  171. 171.
    Wolfe, B. B., Harden, T. K., Sporn, J. R., Molinoff, P. B.: Presynaptic Modulation of Beta Adrenergic Receptors in Rat Cerebral Cortex After Treatment with Antidepressants. J. Pharmac. exp. Ther. 207: S. 446–457, 1978.Google Scholar
  172. 172.
    Wyatt, R. J., Postnoy, B., Kupfer, D. J., Snyder, F., Engelman, K.: Resting Plasma Catecholamine Concentrations in Patients with Depression and Anxiety. Arch. Gen. Psychiatry 24: S. 65–60, 1971.PubMedCrossRefGoogle Scholar
  173. 173.
    Zeller, E. A., Barsky, J., Fouts, J. R., Kirchheimer, W. F., Van Orden, L. S.: Influence of Isonicotinic Acid Hydrazide (INH) and 1-isonicotinyl-2isopropylhydrazine (IIH) on Bacterial an Mammalian Enzymes. Experientia 8: S. 349–361, 1952.CrossRefGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH, Braunschweig 1989

Authors and Affiliations

  • G. Jungkunz
    • 1
  1. 1.LohrDeutschland

Personalised recommendations